News | March 06, 2009

Transoma’s Sleuth AT ICM Implanted in First U.S. Patient

March 6, 2009 - Transoma Medical Inc.’s Sleuth AT wireless, automated implantable cardiac monitoring system was implanted in its first U.S. patient on March 2 at the Ohio State University Medical Center.
Under the supervision of Mahmoud Houmsse, M.D., Troy Rhodes M.D., an electrophysiology fellow, performed the implant. The company received FDA 510(k) marketing clearance for the product on Feb. 11, 2009. A U.S. launch is under way to introduce Sleuth AT to physicians who manage patients with complex arrhythmias as well as patients who experience infrequent, unexplained symptoms such as fainting or palpitations.
“The implant went very well and took only about 15 minutes,” reported Dr. Houmsse. “This new system also offers the option of a longer 8 cm antenna which showed very impressive, high-quality ECG signals even before the incision was closed.”
With Sleuth AT, physicians can now choose to program the capture of high-quality ECG strips at frequent intervals, providing insight into complex arrhythmias, which are often asymptomatic and frequently changing. These captured ECG strips are automatically transferred to a 24/7 monitoring center, staffed by certified cardiac technicians, who classify and notify physicians of the presence of a wide variety of cardiac arrhythmias such as ventricular tachycardia, bradycardia, supraventricular tachycardia and atrial fibrillation (AF).
“Transoma’s enhanced Sleuth system is an exciting new development for physicians who manage difficult and changing complex arrhythmias such as atrial fibrillation,” said John Hummel, M.D., also from the Ohio State University Medical Center. “Although some therapies appear to be curative, one needs to be certain that the benefits are lasting. With Sleuth AT, I can sample 20-second ECG strips as often as every 7.5 minutes and be alerted through the monitoring center of recurrence of these arrhythmias. The Sleuth AT will provide baseline cardiac information prior to a planned AF ablation procedure and will help me monitor for recurrence of AF after the procedure. Regardless of the outcome, the access to long-term monitoring will allow me to manage the patient’s need for medications, including anticoagulation therapy.”
As a complete, remote and automated system, the Sleuth AT Cardiac Monitoring System includes the implantable loop recorder, the personal diagnostic manager, the base station and a 24/7 monitoring center operated by Medicomp.

At the third-party monitoring center, certified cardiac technicians review the patient’s ECG data and provide information to the physician to aid in diagnosis and ongoing treatment. Physicians can access this information via a secure Web portal, and have the reports faxed or e-mailed to them as they prefer. If the cardiac technician observes a particularly concerning arrhythmia, the patient’s physician will be contacted immediately.

For more information: www.transoma.com.

Related Content

Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Heart Rhythm 2019 study shows travelers with common cardiac devices can pass through without restrictions or precautions. HRS 2019, #HRS #HRS19

A new study shows travelers with common cardiac devices can pass through airport body scanners without restrictions or precautions.

News | EP Lab | May 14, 2019
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), su
News | EP Lab | May 13, 2019
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their
Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Feature | EP Lab | March 22, 2019
March 22, 2019 — The U.S.
Overlay Init